Suppr超能文献

评价中医个体化治疗:N-of-1 试验的初步研究。

Evaluating the Individualized Treatment of Traditional Chinese Medicine: A Pilot Study of N-of-1 Trials.

机构信息

Department of Respiratory Disease, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China.

Department of Pharmacy, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China.

出版信息

Evid Based Complement Alternat Med. 2014;2014:148730. doi: 10.1155/2014/148730. Epub 2014 Nov 11.

Abstract

Purpose. To compare the efficacy of individualized herbal decoction with controlled decoction for individual patients with stable bronchiectasis. Methods. We conducted N-of-1 RCTs (single-patient, double-blind, randomized, multiple crossover design) in 3 patients with stable bronchiectasis. The primary outcome was patient self-rated symptom scores on visual analogue scales. Secondary outcome was 24-hour sputum volume. A clinical efficacy criterion which combined symptoms score and medication preference was also formulated. Results. All three patients showed various degrees of improvement on their symptoms and one patient's (Case 3) 24 h sputum volume decreased from 70 mL to 30 mL. However, no significant differences were found between individualized herbal decoction and control decoction on symptoms score, or on 24-hour sputum volume. One patient (Case 2) had clear preference for the individualized herbal decoction over the standard one with the confirmation after unblinding. We therefore considered this case as clinically important. Discussion. N-of-1 trials comply with individualized philosophy of TCM clinical practice and had good compliance. It is necessary to set up clinical efficacy criteria and to consider the interference of acute exacerbation.

摘要

目的。比较个体化中药汤剂与个体化患者控制汤剂治疗稳定型支气管扩张症的疗效。

方法。我们对 3 例稳定型支气管扩张症患者进行了 N-of-1 RCT(单患者、双盲、随机、多次交叉设计)。主要结局是患者在视觉模拟量表上的自我报告症状评分。次要结局是 24 小时痰液量。还制定了一个结合症状评分和药物偏好的临床疗效标准。

结果。所有 3 例患者的症状均有不同程度的改善,1 例患者(病例 3)的 24 小时痰液量从 70 毫升减少到 30 毫升。然而,个体化中药汤剂与对照汤剂在症状评分或 24 小时痰液量方面无显著差异。1 例患者(病例 2)对个体化中药汤剂的偏好明显高于标准汤剂,在揭盲后得到了确认。因此,我们认为该病例具有临床意义。

讨论。N-of-1 试验符合中医临床实践的个体化理念,具有良好的依从性。有必要制定临床疗效标准,并考虑急性加重的干扰。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c79/4244929/d0ce1caf19d8/ECAM2014-148730.001.jpg

相似文献

1
Evaluating the Individualized Treatment of Traditional Chinese Medicine: A Pilot Study of N-of-1 Trials.
Evid Based Complement Alternat Med. 2014;2014:148730. doi: 10.1155/2014/148730. Epub 2014 Nov 11.
2
Investigation into the Individualized Treatment of Traditional Chinese Medicine through a Series of N-of-1 Trials.
Evid Based Complement Alternat Med. 2018 Feb 7;2018:5813767. doi: 10.1155/2018/5813767. eCollection 2018.
3
Evaluating the Effects of Heat-Clearing Traditional Chinese Medicine in Stable Bronchiectasis by a Series of N-of-1 Trials.
Evid Based Complement Alternat Med. 2022 Jan 17;2022:6690638. doi: 10.1155/2022/6690638. eCollection 2022.
7
Oral traditional Chinese medication for adhesive small bowel obstruction.
Cochrane Database Syst Rev. 2012 May 16;2012(5):CD008836. doi: 10.1002/14651858.CD008836.pub2.
10
A Series of N-of-1 Trials for Traditional Chinese Medicine Using a Bayesian Method: Study Rationale and Protocol.
Evid Based Complement Alternat Med. 2021 Apr 17;2021:9976770. doi: 10.1155/2021/9976770. eCollection 2021.

引用本文的文献

1
Consolidated guidance for behavioral intervention pilot and feasibility studies.
Pilot Feasibility Stud. 2024 Apr 6;10(1):57. doi: 10.1186/s40814-024-01485-5.
4
Evaluating the Effects of Heat-Clearing Traditional Chinese Medicine in Stable Bronchiectasis by a Series of N-of-1 Trials.
Evid Based Complement Alternat Med. 2022 Jan 17;2022:6690638. doi: 10.1155/2022/6690638. eCollection 2022.
5
Methodological Considerations in N-of-1 Trials of Traditional Chinese Medicine.
Evid Based Complement Alternat Med. 2021 Jun 23;2021:6634134. doi: 10.1155/2021/6634134. eCollection 2021.
6
A Series of N-of-1 Trials for Traditional Chinese Medicine Using a Bayesian Method: Study Rationale and Protocol.
Evid Based Complement Alternat Med. 2021 Apr 17;2021:9976770. doi: 10.1155/2021/9976770. eCollection 2021.
7
Practice-Based Research in Complementary Medicine: Could N-of-1 Trials Become the New Gold Standard?
Healthcare (Basel). 2020 Jan 8;8(1):15. doi: 10.3390/healthcare8010015.
8
Whole Systems Research Methods in Health Care: A Scoping Review.
J Altern Complement Med. 2019 Mar;25(S1):S21-S51. doi: 10.1089/acm.2018.0499.
10
N-of-1 trials in the clinical care of patients in developing countries: a systematic review.
Trials. 2018 Apr 23;19(1):246. doi: 10.1186/s13063-018-2596-5.

本文引用的文献

1
An n-of-1 Trial Service in Clinical Practice: Testing the Effectiveness of Liuwei Dihuang Decoction for Kidney-Yin Deficiency Syndrome.
Evid Based Complement Alternat Med. 2013;2013:827915. doi: 10.1155/2013/827915. Epub 2013 Sep 23.
2
British Thoracic Society guideline for non-CF bronchiectasis.
Thorax. 2010 Jul;65(7):577. doi: 10.1136/thx.2010.142778.
3
A tutorial on pilot studies: the what, why and how.
BMC Med Res Methodol. 2010 Jan 6;10:1. doi: 10.1186/1471-2288-10-1.
4
New era of personalized medicine: a 10-year anniversary.
Oncologist. 2009 May;14(5):557-8. doi: 10.1634/theoncologist.2009-0047.
5
Pharmacogenomics and personalized medicine: mapping of future value creation.
Biotechniques. 2005 Oct;39(10 Suppl):S1-6. doi: 10.2144/000112048.
7
Effect of oxygen on health quality of life in patients with chronic obstructive pulmonary disease with transient exertional hypoxemia.
Am J Respir Crit Care Med. 2007 Aug 15;176(4):343-9. doi: 10.1164/rccm.200702-308OC. Epub 2007 Apr 19.
9
The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience.
Ann Intern Med. 1990 Feb 15;112(4):293-9. doi: 10.7326/0003-4819-112-4-293.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验